WO1998009619A1 - Novel methods - Google Patents
Novel methods Download PDFInfo
- Publication number
- WO1998009619A1 WO1998009619A1 PCT/US1997/015475 US9715475W WO9809619A1 WO 1998009619 A1 WO1998009619 A1 WO 1998009619A1 US 9715475 W US9715475 W US 9715475W WO 9809619 A1 WO9809619 A1 WO 9809619A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cardiovascular disease
- compound
- formula
- effects
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to therapeutic agents that are tissue selective estrogen agonist/antagonist compounds that have been found to be useful in the treatment and prevention of cardiovascular disease in postmenopausal women.
- This invention provides a method for the prevention and treatment of cardiovascular disease in postmenopausal women without having an overt uterotrophic effect, or promoting an increased risk of breast cancer or causing an increased incidence of vaginal bleeding and breast tenderness
- the method comprises administering to a human in need thereof an effective amount of a compound of formula I
- X represents 3- or 4- lodo or bromo and the R-* and Rr symbols, which may be the same or different, represent Cj-3 alkyl, especially methyl or ethyl, groups or R 1 - represents a hydrogen atom and R2 a C1.3 alkyl group or R-- and R2 together with the nitrogen atom to which they are attached represent a saturated heterocyclic group, typically having 5 or 6 ring atoms, especially a pyrrolidmo, pipendino, 4- methylpipe ⁇ dino or morpholino group, and their pharmaceutically acceptable acid addition salts
- the present invention is a therapeutic method for preventing and treating cardiovascular disease in postmenopausal women with a group of compounds that have been previously prepared and evaluated as effective in the treatment of estrogen receptor-positive breast cancer These compounds are described in formula I above and in U S. patent 4,839,155
- the preferred compound for the described method of treatment is
- Such compounds are known to bind to the estrogen receptor and to cause either estrogen agonist or antagonist effects depending on the tissue bemg studied
- a beneficial effect on cardiovascular disease would be produced by estrogen agonist effects on the liver ( to alter the hpid profile and levels of fibinogen)
- estrogen agonist effects on the arterial wall may also contribute to a reduction in the risk of cardiovascular disease.
- cardiovascular disease refers to atherosclerotic cardiovascular diseases such as myocardial infarction, stroke, angina, intermittent claudication transient blindness, transient lschemic attacks (TIA) and peripheral vascular disease.
- the method of this invention is useful in producing a plasma lipid profile that is associated with a reduced risk of atherosclerosis and a reduction of raised LDL cholesterol levels Additionally this method is useful in producing a reduction of other independent cardiovascular risk factors such as plasma fibnnogen levels and serum levels of lp(a).
- the ability to reduce the risk of cardiovascular disease is assessed by studies of the effect of idoxifene a number of different risk factors for cardiovascular disease in postmenopausal women. These include different parameters of the pid profile and levels of coagulation and fib ⁇ nolysis markers.
- the compounds of the instant invention and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
- a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carner(s) for example, ethanol, glycerine, non-aqueous solvent, for example, polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or colonng agent
- a suitable liquid carner(s) for example, ethanol, glycerine, non-aqueous solvent, for example, polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or colonng agent
- a composition in the form of a tablet can be prepared using any suitable pharmaceutical car ⁇ er(s) routinely used for prepa ⁇ ng solid formulations Examples of such earners include magnesium stearate, starch, lactose, sucrose and cellulose
- a composition in the form of a capsule can be prepared using routine encapsulation procedures.
- pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule: alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carner(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- a suitable pharmaceutical carner(s) for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- the compounds of the instant invention and their pharmaceutically acceptable salts which are active when administered parenterally can be formulated as solutions or suspensions.
- a composition for parenteral administration will generally consist of a solution or suspension of the active ingredient in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrro done, lecithin, arachis oil or sesame oil.
- a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrro done, lecithin, arachis oil or sesame oil.
- the solution can be lyophi sed and then reconstituted with a suitable solvent just prior to administration
- a typical suppository composition comprises a compound of the instant invention or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or coca butter or other low melting vegetable or synthetic waxes or fats
- a typical transdermal formulation comprises a conventional aqueous or non- aqueous vehicle, for example, a cream, ointment lotion or paste or in the form of a medicated plaster, patch or membrane
- the pharmaceutical compositions adapted include solutions, suspensions, ointments, and solid inserts
- Typical pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or vegetable oils, and water soluble ophthalmologically acceptable non-toxic polymers, for example, cellulose derivatives such as methyl cellulose
- the pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting and bodying agents, as for example, polyethylene glycols, antibacterial components such as quaternary ammonium compounds; buffering ingredients such as alkali metal chloride, antioxidants such as sodium metabisulfite, and other conventional ingredients such as sorbitan monolaurate
- the composition is in unit dose form.
- Doses of the compounds of the instant invention in a pharmaceutical dosage unit will be an efficacious, non- toxic quantity selected from the range of 01 - 200 mg/kg of active compound, preferably 1 - 100 mg/kg.
- the selected dose is administered to a human patient in need of treatment or prevention of cardiovascular disease is or in the lowering of plasma cholesterol from 1-6 times daily, orally, rectally, topically, by injection, or continuously by infusion
- Oral dosage units for human administration preferably contain from 10 to 500 mg of active compound Lower dosages are used generally for parenteral administration
- Oral administration is used when safe, effective, and convenient for the patient
- An oral dosage form for administering orally active Formula (I) compounds is produced by screening, mixing and filling into hard gelatin capsules the ingredients in proportions, for example, as shown below
- sucrose calcium sulfate dihydrate and orally active Formula (I) compounds are mixed and granulated with a 10% gelatmg solution.
- the wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97942388A EP0927029A4 (en) | 1996-09-06 | 1997-09-03 | NEW PROCEDURE |
JP51283898A JP2002515047A (ja) | 1996-09-06 | 1997-09-03 | 新規方法 |
AU44097/97A AU4409797A (en) | 1996-09-06 | 1997-09-03 | Novel methods |
BR9711681A BR9711681A (pt) | 1996-09-06 | 1997-09-03 | Novos m-todos |
CA002264943A CA2264943A1 (en) | 1996-09-06 | 1997-09-03 | Novel methods |
NO991096A NO991096D0 (no) | 1996-09-06 | 1999-03-05 | Nye fremgangsmÕter |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2543996P | 1996-09-06 | 1996-09-06 | |
US60/025,439 | 1996-09-06 | ||
US5066697P | 1997-06-24 | 1997-06-24 | |
US60/050,666 | 1997-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998009619A1 true WO1998009619A1 (en) | 1998-03-12 |
Family
ID=26699738
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/015474 WO1998009519A1 (en) | 1996-09-06 | 1997-09-03 | Method of treating post menopausal diseases, including osteoporosis |
PCT/US1997/015475 WO1998009619A1 (en) | 1996-09-06 | 1997-09-03 | Novel methods |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/015474 WO1998009519A1 (en) | 1996-09-06 | 1997-09-03 | Method of treating post menopausal diseases, including osteoporosis |
Country Status (16)
Country | Link |
---|---|
EP (2) | EP0927029A4 (xx) |
JP (2) | JP2002515046A (xx) |
KR (2) | KR20000068472A (xx) |
CN (2) | CN1236299A (xx) |
AR (1) | AR008155A1 (xx) |
AU (2) | AU4247397A (xx) |
BR (2) | BR9711676A (xx) |
CA (2) | CA2264943A1 (xx) |
CO (2) | CO4920218A1 (xx) |
CZ (1) | CZ76699A3 (xx) |
IL (1) | IL128645A0 (xx) |
NO (2) | NO991097L (xx) |
PL (2) | PL332278A1 (xx) |
TR (2) | TR199900504T2 (xx) |
TW (1) | TW411273B (xx) |
WO (2) | WO1998009519A1 (xx) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19905961A1 (de) * | 1999-02-12 | 2000-08-17 | Stefan Neubauer | Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz |
US6569904B1 (en) * | 1998-12-09 | 2003-05-27 | Orion Corporation | Agent for lowering endothelin levels |
US6620806B2 (en) | 2000-10-17 | 2003-09-16 | Pfizer Inc. | Methods and kits for improving vascular health |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998034608A1 (en) * | 1997-02-11 | 1998-08-13 | Novo Nordisk A/S | Methods for treatment or prophylaxis of menopausal symptoms |
US6528681B2 (en) * | 2000-04-05 | 2003-03-04 | Bristol-Meyers Squibb Pharma Company | Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839155A (en) * | 1986-09-11 | 1989-06-13 | National Research Development Corporation | Iodotamoxifen derivatives and use for estrogen receptor-positive breast cancer detection and therapy |
US5470883A (en) * | 1994-05-23 | 1995-11-28 | Stromberg; Brent V. | Method of treating peripheral vasoconstriction with tamoxifen citrate |
US5604248A (en) * | 1994-05-05 | 1997-02-18 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
US5681835A (en) * | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5681863A (en) * | 1992-09-15 | 1997-10-28 | Merrell Pharmaceuticals Inc. | Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11510479A (ja) * | 1995-06-07 | 1999-09-14 | ネオルックス コーポレイション | タモキシフェン類似体による心臓血管疾病の予防及び治療 |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
US6069175A (en) * | 1996-11-15 | 2000-05-30 | Pfizer Inc. | Estrogen agonist/antagonists treatment of atherosclerosis |
-
1997
- 1997-08-29 AR ARP970103968A patent/AR008155A1/es unknown
- 1997-09-03 JP JP51283798A patent/JP2002515046A/ja active Pending
- 1997-09-03 PL PL97332278A patent/PL332278A1/xx unknown
- 1997-09-03 CN CN97199492A patent/CN1236299A/zh active Pending
- 1997-09-03 CZ CZ99766A patent/CZ76699A3/cs unknown
- 1997-09-03 KR KR1019997001860A patent/KR20000068472A/ko not_active Application Discontinuation
- 1997-09-03 PL PL97332038A patent/PL332038A1/xx unknown
- 1997-09-03 BR BR9711676A patent/BR9711676A/pt not_active Application Discontinuation
- 1997-09-03 AU AU42473/97A patent/AU4247397A/en not_active Abandoned
- 1997-09-03 TR TR1999/00504T patent/TR199900504T2/xx unknown
- 1997-09-03 CA CA002264943A patent/CA2264943A1/en not_active Abandoned
- 1997-09-03 CN CN97199493A patent/CN1236313A/zh active Pending
- 1997-09-03 EP EP97942388A patent/EP0927029A4/en not_active Withdrawn
- 1997-09-03 AU AU44097/97A patent/AU4409797A/en not_active Abandoned
- 1997-09-03 KR KR1019997001861A patent/KR20000068473A/ko not_active Application Discontinuation
- 1997-09-03 JP JP51283898A patent/JP2002515047A/ja active Pending
- 1997-09-03 BR BR9711681A patent/BR9711681A/pt not_active Application Discontinuation
- 1997-09-03 EP EP97940773A patent/EP0929216A4/en not_active Withdrawn
- 1997-09-03 TR TR1999/00506T patent/TR199900506T2/xx unknown
- 1997-09-03 CA CA002264775A patent/CA2264775A1/en not_active Abandoned
- 1997-09-03 WO PCT/US1997/015474 patent/WO1998009519A1/en not_active Application Discontinuation
- 1997-09-03 IL IL12864597A patent/IL128645A0/xx unknown
- 1997-09-03 WO PCT/US1997/015475 patent/WO1998009619A1/en not_active Application Discontinuation
- 1997-09-04 CO CO97051287A patent/CO4920218A1/es unknown
- 1997-09-04 CO CO97051289A patent/CO5070658A1/es unknown
- 1997-12-11 TW TW086112930A patent/TW411273B/zh active
-
1999
- 1999-03-05 NO NO991097A patent/NO991097L/no not_active Application Discontinuation
- 1999-03-05 NO NO991096A patent/NO991096D0/no not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839155A (en) * | 1986-09-11 | 1989-06-13 | National Research Development Corporation | Iodotamoxifen derivatives and use for estrogen receptor-positive breast cancer detection and therapy |
US5681863A (en) * | 1992-09-15 | 1997-10-28 | Merrell Pharmaceuticals Inc. | Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors |
US5681835A (en) * | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5604248A (en) * | 1994-05-05 | 1997-02-18 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
US5470883A (en) * | 1994-05-23 | 1995-11-28 | Stromberg; Brent V. | Method of treating peripheral vasoconstriction with tamoxifen citrate |
Non-Patent Citations (1)
Title |
---|
See also references of EP0927029A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569904B1 (en) * | 1998-12-09 | 2003-05-27 | Orion Corporation | Agent for lowering endothelin levels |
DE19905961A1 (de) * | 1999-02-12 | 2000-08-17 | Stefan Neubauer | Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz |
US6620806B2 (en) | 2000-10-17 | 2003-09-16 | Pfizer Inc. | Methods and kits for improving vascular health |
Also Published As
Publication number | Publication date |
---|---|
KR20000068473A (ko) | 2000-11-25 |
AU4247397A (en) | 1998-03-26 |
NO991096L (no) | 1999-03-05 |
CA2264943A1 (en) | 1998-03-12 |
PL332038A1 (en) | 1999-08-16 |
NO991097D0 (no) | 1999-03-05 |
AR008155A1 (es) | 1999-12-09 |
TW411273B (en) | 2000-11-11 |
BR9711676A (pt) | 1999-08-24 |
NO991097L (no) | 1999-03-05 |
JP2002515046A (ja) | 2002-05-21 |
TR199900506T2 (xx) | 1999-07-21 |
WO1998009519A1 (en) | 1998-03-12 |
NO991096D0 (no) | 1999-03-05 |
IL128645A0 (en) | 2000-01-31 |
JP2002515047A (ja) | 2002-05-21 |
AU4409797A (en) | 1998-03-26 |
BR9711681A (pt) | 1999-08-24 |
EP0929216A4 (en) | 2001-04-04 |
EP0927029A1 (en) | 1999-07-07 |
CA2264775A1 (en) | 1998-03-12 |
CZ76699A3 (cs) | 1999-08-11 |
CO4920218A1 (es) | 2000-05-29 |
EP0929216A1 (en) | 1999-07-21 |
CN1236299A (zh) | 1999-11-24 |
PL332278A1 (en) | 1999-08-30 |
TR199900504T2 (xx) | 1999-06-21 |
EP0927029A4 (en) | 2001-06-13 |
KR20000068472A (ko) | 2000-11-25 |
CO5070658A1 (es) | 2001-08-28 |
CN1236313A (zh) | 1999-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1337591C (en) | Therapeutic composition comprising oestrogen and antioestrogen | |
RU2157203C2 (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза | |
RU2122854C1 (ru) | Комбинированный препарат для контрацепции, фармацевтическая упаковка для контрацепции | |
KR100352571B1 (ko) | 배합호르몬피임약제 | |
JPH06234632A (ja) | ベンゾチオフェン類を含有する医薬組成物 | |
HUT71229A (en) | Pharmaceutical compositions for the treatment of peri-menopausal syndrome containing 2-phenyl-3-aroyl-benzotiophene derivatives and process for their preparation | |
KR20020084230A (ko) | 호르몬 보충요법 | |
JP2003508441A (ja) | 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ | |
EP1340508A1 (en) | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications | |
JPH092947A (ja) | 高コレステロール血症治療剤 | |
MXPA03008366A (es) | Terapia de reemplazamiento de estrogenos. | |
WO1998009619A1 (en) | Novel methods | |
JP2000513331A (ja) | 鬱病の治療におけるパロキセチン | |
HUT53285A (en) | Process for producing pharmaceutical compositions comprising ace inhibitor and suitable for treating toxicomania | |
JPS6348218A (ja) | 閉塞性血管病処置用医薬組成物 | |
SK2572002A3 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
MXPA99002214A (en) | Novel methods | |
JPH09500112A (ja) | ざ瘡治療用ホルモン剤及びその使用法 | |
WO1999000019A1 (en) | Methods of treating the symptoms of atrophic vaginitis and altered sexual behavior in postmenopausal women | |
WO1999009993A1 (en) | Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception | |
WO1998049896A1 (en) | A method of treating vasomotor symptoms | |
US6121328A (en) | Racemic propranolol | |
WO1999000018A1 (en) | Methods of treating symptoms of impaired memory, concentration and cognition in postmenopausal women | |
AU619586B2 (en) | Pharmaceutical product which can be applied transdermally containing pharmaceutically usable glycosides | |
JP3177686B2 (ja) | 月経困難症予防または治療剤と月経困難症予防機能性食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97199493.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR CA CN CZ EE GE GH HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 334329 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-767 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2264943 Country of ref document: CA Ref document number: 2264943 Country of ref document: CA Kind code of ref document: A Ref document number: 1998 512838 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/002214 Country of ref document: MX Ref document number: 1019997001861 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999/00506 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997942388 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997942388 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: PV1999-767 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997001861 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997942388 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019997001861 Country of ref document: KR |